1
|
Sun Y, Wang B, Pei J, Luo Y, Yuan N, Xiao Z, Wu H, Luo C, Wang J, Wei S, Pei Y, Fu S, Wang D. Molecular dynamic and pharmacological studies on protein-engineered hirudin variants of Hirudinaria manillensis and Hirudo medicinalis. Br J Pharmacol 2022; 179:3740-3753. [PMID: 35135035 DOI: 10.1111/bph.15816] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2021] [Revised: 01/31/2022] [Accepted: 02/01/2022] [Indexed: 12/01/2022] Open
Abstract
BACKGROUND AND PURPOSE Hirudin variants are the most powerful thrombin inhibitors discovered to date, with a lower risk of bleeding than heparin. For anticoagulation, the C-termini of hirudins bind to the exocite I of thrombin. Anticoagulant effects of gene-recombinant hirudin are weaker than natural hirudin for the reason of lacking tyrosine-O-sulfation at C terminus. EXPERIMENTAL APPROACH The integrative pharmacological study applied molecular dynamic, molecular biological, and in vivo and in vitro experiments to elucidate the anticoagulant effects of protein-engineered hirudins. KEY RESULTS Molecular dynamic (MD) analysis showed that modifications of the C-termini of hirudin variant 1 of Hirudo medicinalis (HV1) and hirudin variant 2 of Hirudinaria manillensis (HM2) changed the binding energy of the C-termini to human thrombin. The study indicated Asp61 of HM2 that corresponds to sulfated Tyr63 of HV1 is critical for inhibiting thrombin activities, and the anticoagulant effects of HV1 and HM2 were improved when the amino acid residues adjacent to Asp61 were mutated to Asp, such as the prolongation of the activated partial thromboplastin time (APTT), prothrombin time (PT) and thrombin time (TT) of human blood, and decreased Ki and IC50 values. In the in vivo experiments, mutations at C-termini of HV1 and HM2 significantly changed APTT, PT and TT. CONCLUSION AND IMPLICATIONS The study indicated that the anticoagulant effects of gene-engineered HM2 are stronger than gene-engineered HV1, and HM2-E60D-I62D has the strongest effects and could be an antithrombotic medicine with better therapeutic effects.
Collapse
Affiliation(s)
- Yan Sun
- Laboratory of Biopharmaceutics and Molecular Pharmacology, School of Pharmaceutical Sciences, Hainan University, Haikou, Hainan, China
| | - Baochun Wang
- The First Department of Gastrointestinal Surgery, Hainan General Hospital, Haikou, Hainan, China
| | - Jinli Pei
- Laboratory of Biopharmaceutics and Molecular Pharmacology, School of Pharmaceutical Sciences, Hainan University, Haikou, Hainan, China.,Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China
| | - Ying Luo
- Laboratory of Biopharmaceutics and Molecular Pharmacology, School of Pharmaceutical Sciences, Hainan University, Haikou, Hainan, China
| | - Nan Yuan
- Laboratory of Biopharmaceutics and Molecular Pharmacology, School of Pharmaceutical Sciences, Hainan University, Haikou, Hainan, China
| | - Zhengpan Xiao
- Laboratory of Biopharmaceutics and Molecular Pharmacology, School of Pharmaceutical Sciences, Hainan University, Haikou, Hainan, China
| | - Hao Wu
- Laboratory of Biopharmaceutics and Molecular Pharmacology, School of Pharmaceutical Sciences, Hainan University, Haikou, Hainan, China.,Central Laboratory, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, China
| | - Chenghui Luo
- Laboratory of Biopharmaceutics and Molecular Pharmacology, School of Pharmaceutical Sciences, Hainan University, Haikou, Hainan, China
| | - Jiaxuan Wang
- Laboratory of Biopharmaceutics and Molecular Pharmacology, School of Pharmaceutical Sciences, Hainan University, Haikou, Hainan, China
| | - Shuangshuang Wei
- Laboratory of Biopharmaceutics and Molecular Pharmacology, School of Pharmaceutical Sciences, Hainan University, Haikou, Hainan, China
| | - Yechun Pei
- Laboratory of Biopharmaceutics and Molecular Pharmacology, School of Pharmaceutical Sciences, Hainan University, Haikou, Hainan, China
| | - Shengmiao Fu
- Department of Medical Laboratory Science, Hainan General Hospital, Haikou, Hainan, China
| | - Dayong Wang
- Laboratory of Biopharmaceutics and Molecular Pharmacology, School of Pharmaceutical Sciences, Hainan University, Haikou, Hainan, China.,Key laboratory of Tropical Biological Resources of the Ministry of Education of China, Hainan University, Haikou, Hainan, China
| |
Collapse
|
2
|
Zhang J, Lan N. Hirudin variants production by genetic engineered microbial factory. Biotechnol Genet Eng Rev 2018; 34:261-280. [PMID: 30095033 DOI: 10.1080/02648725.2018.1506898] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Hirudin was discovered as an active anticoagulant in leech extracts almost 60 years ago. Since their initial discovery, hirudin and its variants have been produced with various anti-thrombotic, cancer cell inhibition, diabetic cataract treatment and anti-fatigue activities. Some hirudin variants have been approved for clinical use and released into the marketplace. Recent progress has seen made in relation to hirudin variants expressed in several well-established microbial hosts, including Escherichia coli, Saccharomyces cerevisiae, Pichia pastoris and others, with high levels of activity and yield. This review summarizes the current progress on hirudin production using microbial producers, and considers the outlook for future development.
Collapse
Affiliation(s)
- Jianguo Zhang
- a Institute of Food Science and Engineering, School of Medical Instrument and Food Engineering , University of Shanghai for Science and Technology , Shanghai , China
| | - Nana Lan
- a Institute of Food Science and Engineering, School of Medical Instrument and Food Engineering , University of Shanghai for Science and Technology , Shanghai , China
| |
Collapse
|